82% of MG Patients Hit Key Improvement Milestone in BRIUMVI Phase 1—Phase 2 Trial Launched to Build on Momentum
Positive Phase 1 Data Reveals Meaningful Improvements in Myasthenia Gravis Patients
TG Therapeutics is drawing attention in the biotech world after announcing strong Phase 1 results for its subcutaneous BRIUMVI therapy in patients with myasthenia gravis (MG). In this early study, an impressive 82% of subjects achieved what researchers call a "minimal clinically important difference" (MCID) in their MG-ADL scores—a key benchmark for improvement in daily muscle function. Patients saw a mean improvement of 4.6 points on this scale by week 24, highlighting both the potential and speed of this new approach.
Detailed Results: Rapid and Sustained Clinical Benefits Observed
The Phase 1 study enrolled 11 patients, each with antibody-positive MG and an average age of 74. At the outset, these patients faced a considerable disease burden, with average MG-ADL scores at 8.24 and QMG scores at 12.00. After treatment with subcutaneous BRIUMVI:
- 82% of patients achieved MCID (at least a 2-point improvement in MG-ADL)
- The median time to improvement was just 30 days
- Overall, patients experienced a mean 4.6-point improvement in MG-ADL at Week 24
| Metric | Baseline | Week 24 | Improvement | % Achieving MCID |
|---|---|---|---|---|
| MG-ADL (mean) | 8.24 | 3.64 | 4.6 | 82% |
Importantly, BRIUMVI was generally well-tolerated, with a safety profile consistent with existing IV BRIUMVI treatments. This sets the stage for its potential expansion beyond multiple sclerosis into the myasthenia gravis field—where a durable solution has proven elusive.
Phase 2 Trial Targets Long-Term Disease Control with Sequential Therapy Design
Building on these results, TG Therapeutics has launched a Phase 2 study to test BRIUMVI as a maintenance therapy following an initial induction with the FcRn inhibitor efgartigimod. This trial aims to determine if BRIUMVI can maintain the clinical improvements seen after efgartigimod—potentially reducing the need for frequent re-treatment, a key unmet need for MG patients.
The Phase 2 study will enroll approximately 120 participants, all of whom will first receive efgartigimod. Those who respond will move on to a randomized period of either BRIUMVI or placebo for 24 weeks, with subsequent eligibility for a 72-week open-label extension.
| Phase 2 Design | Details |
|---|---|
| Patients Enrolled | ~120 |
| Induction Treatment | Efgartigimod x 4 weeks |
| Randomization | BRIUMVI vs Placebo (24 weeks) |
| Main Endpoint | Time to clinical worsening (=2-point MG-ADL increase or myasthenic crisis) |
| Extension | 72-week open-label BRIUMVI |
Looking Ahead: A Potential Shift in MG Care, but Cautions Remain
While this early data is promising, the road from Phase 1 to a new standard of care is never simple. The positive results must be confirmed in a much larger group of patients and over a longer time frame. It’s also important to note BRIUMVI’s safety considerations—including risks of infusion reactions and infections, among others—that physicians will continue to monitor as clinical trials expand.
Still, for patients and clinicians seeking more durable and manageable options for myasthenia gravis, BRIUMVI’s rapid, sustained benefit profile and the upcoming Phase 2 trial could represent the beginning of a new treatment paradigm. Investors and healthcare professionals will want to watch for the full results as TG Therapeutics continues to push the envelope for MG therapy.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI